Yahoo
OTC Markets OTCPK - Delayed Quote USD

Anebulo Pharmaceuticals, Inc. (ANEB)

0.2420 -0.0180 (-6.92%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for ANEB
  • Previous Close 0.2600
  • Open 0.8699
  • Bid 0.3502 x 250000
  • Ask 0.5199 x 250000
  • Day's Range 0.8699 - 0.8699
  • 52 Week Range 0.0010 - 2.6500
  • Volume 100
  • Avg. Volume 184
  • Market Cap (intraday) 9.87M
  • Beta (5Y Monthly) -1.89
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1900
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

www.anebulo.com

2

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANEB
76.04%
S&P 500 (^GSPC)
10.73%

1-Year Return

ANEB
90.83%
S&P 500 (^GSPC)
11.11%

3-Year Return

ANEB
88.87%
S&P 500 (^GSPC)
81.91%

5-Year Return

ANEB
96.36%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -2.16M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-2M
-2M
-1M
-500K
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.04%

  • Return on Equity (ttm)

    -69.69%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.98M

  • Diluted EPS (ttm)

    -0.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.04M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.77M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: